Unilever strengthens work on topical delivery systems

By Katie Bird

- Last updated on GMT

Related tags: Chief executive officer, Pharmacology, Unilever

Unilever has signed a research agreement with a US company in order to explore transdermal delivery technologies.

Massachusetts-based BioChemics developed its transdermal drug delivery system VALE (Vasi-active Lipid Encapusulated) initially for use in the pharmaceutical sector, but it believes it has potential cosmetic applications.

The company has signed the agreement with the Anglo-Dutch consumer goods giant to investigate the use of BioChemics’ topical delivery platform in Unilever’s products.

"We are delighted to be working with Unilever to evaluate the broader applications of our technology for their products,"​ said President and Chief Executive Officer John J. Masiz.

In addition, Masiz claims the agreement with Unilever further validates the technology in the eyes of other partners looking for a topical delivery technology for their consumer products.

Amore Pacific collaboration

This is not the first foray into the cosmetics arena for the young company which signed a similar agreement with Pacific Pharmaceuticals and its parent company Amore Pacific, earlier this year.

Amore Pacific is a leading cosmetics and healthcare company based in South Korea and the deal was an attempt to move the technology into new arenas.

At the time, company CEO Masiz said BioChemics was excited about the collaboration as it spelled new applications for the VALE technology.

Related topics: Formulation & Science

Related news

Follow us

Products

View more

Webinars